Print

Argos Therapeutics, Inc. Identifies Immune Response Marker Connected to Prolonged Overall Survival in mRCC Patients Treated With AGS-003  
10/11/2012 9:16:24 AM

DURHAM, N.C., Oct. 11, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that it has identified a unique immune response signature that significantly correlates with clinical outcomes associated with its Arcelis™ immunotherapy product candidate, AGS-003 being developed for the treatment of metastatic renal cell carcinoma (mRCC). Data presented at the Markers in Cancer Meeting, October 11, Hollywood, Fla., demonstrates that a specific tumor-reactive cytotoxic T cell (CTL) subset (CD28+/CCR7+/CD45RA- phenotype) displaying a broad Markers of Immune Function (MIFs) profile correlates with progression-free survival (PFS) and overall survival (OS) in patients treated with AGS-003.
//-->